These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10840389)

  • 1. Therapeutic potential for orally administered type 1 interferons.
    Beilharz MW
    Pharm Sci Technol Today; 2000 Jun; 3(6):193-197. PubMed ID: 10840389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic effects of orally administered interferons and interleukin-2.
    Fleischmann WR; Koren S
    J Interferon Cytokine Res; 1999 Aug; 19(8):829-39. PubMed ID: 10476926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
    Tompkins WA
    J Interferon Cytokine Res; 1999 Aug; 19(8):817-28. PubMed ID: 10476925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Immunogenicity of Interferons.
    Tovey MG; Lallemand C
    Pharmaceuticals (Basel); 2010 Apr; 3(4):1162-1186. PubMed ID: 27713294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo.
    Beilharz MW; McDonald W; Watson MW; Heng J; McGeachie J; Lawson CM
    J Interferon Cytokine Res; 1997 Oct; 17(10):625-30. PubMed ID: 9355964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons and their role In inflammation.
    Tilg H; Kaser A
    Curr Pharm Des; 1999 Oct; 5(10):771-85. PubMed ID: 10526087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis.
    Brod SA; Khan M
    J Autoimmun; 1996 Feb; 9(1):11-20. PubMed ID: 8845048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferons in the pathogenesis and treatment of canine diseases.
    Klotz D; Baumgärtner W; Gerhauser I
    Vet Immunol Immunopathol; 2017 Sep; 191():80-93. PubMed ID: 28895871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of interferons and other cytokines in the regulation of the immune response.
    Belardelli F
    APMIS; 1995 Mar; 103(3):161-79. PubMed ID: 7538771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons.
    Brod SA; Scott M; Burns DK; Phillips JT
    J Interferon Cytokine Res; 1995 Feb; 15(2):115-22. PubMed ID: 8590314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose oral use of interferon inhibits virally induced myocarditis.
    Lawson CM; Beilharz MW
    J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferons as biomarkers and effectors: lessons learned from animal models.
    Berry CM; Hertzog PJ; Mangan NE
    Biomark Med; 2012 Apr; 6(2):159-76. PubMed ID: 22448790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems.
    Bocci V
    Crit Rev Ther Drug Carrier Syst; 1992; 9(2):91-133. PubMed ID: 1378776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferons in multiple sclerosis. A review of the evidence.
    Panitch HS
    Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferons for induction of remission in ulcerative colitis.
    Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
    Bosio E; Beilharz MW; Watson MW; Lawson CM
    J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and regulation of IFNs during viral infections.
    Malmgaard L
    J Interferon Cytokine Res; 2004 Aug; 24(8):439-54. PubMed ID: 15320958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type III IFNs: new layers of complexity in innate antiviral immunity.
    Ank N; Paludan SR
    Biofactors; 2009; 35(1):82-7. PubMed ID: 19319850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration.
    Ottoson UB; Carlstrom K; Damber JE; von Schoultz B
    Br J Obstet Gynaecol; 1984 Nov; 91(11):1111-9. PubMed ID: 6498126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.